Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFO
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
Pfizer reported third-quarter 2026 results on November 3, 2026 and raised full-year 2026 revenue guidance by $1.5 billion at the midpoint to a range of $62.0 to $64.0 billion from $60.5 to $62.5 billion previously.1 The company also raised and narrowed full-year 2026 adjusted diluted EPS guidance to a range of $2.95 to $3.05 from $2.80 to $3.00 previously.1
On the pipeline, Pfizer said in October 2026 it announced topline results from the investigational Phase 3 MagnetisMM-32 study evaluating Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior line of treatment with anti-CD38 therapy and lenalidomide, and the study met its primary endpoint of progression-free survival at a pre-specified interim analysis.1 The safety profile of Elrexfio in that study was consistent with its known profile and no new safety signals were identified.1
Also in October, Pfizer said the FDA expanded approval of Talzenna in combination with Xtandi to treat men with metastatic androgen pathway modulation-naive or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations, based on the pivotal TALAPRO-3 data.1
Pfizer also announced that month that the FDA approved Tukysa in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive breast cancer following induction treatment.1
On corporate matters, Pfizer said Cecile Guegan was appointed Chief Financial Officer, Executive Vice President effective November 1, 2026.1 The company also noted a one-time $650 million Acquired In-Process R&D charge tied to its in-licensing and collaboration agreement with Innovent Biologics, Inc., recorded in the third quarter with an unfavorable EPS impact of approximately $0.10.1 Pfizer stated no share repurchases have been completed in 2026, its remaining share repurchase authorization is $3.3 billion as of November 3, 2026, and current guidance does not anticipate any repurchases in 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.